Qualigen Therapeutics Inc
NASDAQ:QLGN
Qualigen Therapeutics Inc
NASDAQ:QLGN
Price:
0.1957 USD
-2.15%
Market Closed
Updated:
Jun 11, 2024
Qualigen Therapeutics Inc
Total Liabilities & Equity
|
Qualigen Therapeutics Inc
Total Liabilities & Equity Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Total Liabilities & Equity Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Qualigen Therapeutics Inc
NASDAQ:QLGN
|
Total Liabilities & Equity
$2m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Liabilities & Equity
$148.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
21%
|
CAGR 10-Years
18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities & Equity
$56.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities & Equity
$93B
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities & Equity
$23.9B
|
CAGR 3-Years
25%
|
CAGR 5-Years
30%
|
CAGR 10-Years
27%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities & Equity
$34.4B
|
CAGR 3-Years
25%
|
CAGR 5-Years
22%
|
CAGR 10-Years
27%
|
See Also
What is Qualigen Therapeutics Inc's Total Liabilities & Equity?
Total Liabilities & Equity
2m
USD
2m
USD
Based on the financial report for Dec 31, 2023, Qualigen Therapeutics Inc's Total Liabilities & Equity amounts to 2m USD.
What is Qualigen Therapeutics Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
-33%
-33%
Over the last year, the Total Liabilities & Equity growth was -89%. The average annual Total Liabilities & Equity growth rates for Qualigen Therapeutics Inc have been -59% over the past three years , -33% over the past five years .
You don't have any saved screeners yet
